US-based Micro Interventional Devices (MID) has completed the first clinical implantation of its MIA technology for minimally invasive mitral and tricuspid repair.

Made from PolyCor anchors and MyoLast implantable elastomer, the device reduces annular dimensions and regurgitation after it is deployed in the patient's native annulus.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The implantation represents the first clinical enrollment in the company's Study of Transcatheter Tricuspid Annular Repair (STTAR) multi center safety and performance clinical study being conducted in Europe.

MID's chief science officer Willard Hennemann said: "On Tuesday, 6 December we successfully deployed nine MIA Implants in our first patient's tricuspid annulus during a minimally invasive tricuspid repair procedure. 

"We look forward to enrolling additional patients in the STTAR study and to following these patients to assess the long term effect of MIA on valve insufficiency."

"A significant reduction in valve area was observed post procedure. We look forward to enrolling additional patients in the STTAR study and to following these patients to assess the long term effect of MIA on valve insufficiency."

The implantation of MIA took place during a minimally invasive tricuspid repair procedure concomitant with mitral valve repair. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MID's founder, president, and chief executive officer (CEO) Michael Whitman said: "Utilising MIA in the STTAR study is the first step in demonstrating the safety and performance of a catheter-based mitral and tricuspid repair system. 

"This data point is encouraging. We are ever more confident of achieving our goal of a truly percutaneous mitral and tricuspid repair. It is our objective to make MIA safe, simple, and secure."

When the procedure was performed at the Vilnius University Hospital Santariskiu Clinic in Vilnius, no intraoperative complications or adverse events were observed or reported. MIA can address underserved patient population by enabling percutaneous repair procedures.